|By PR Newswire||
|January 16, 2014 02:19 PM EST||
WHITE PLAINS, N.Y., Jan. 16, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive funding through The Screen to Lead program - a new grant program to support drug discovery specifically directed toward medicinal chemistry and/or drug target screening in blood cancers.
LLS recognizes investigators' significant need for resources to develop small molecules into drug-like compounds suitable for preclinical proof-of-concept testing in cancer models. The goal is to fill a gap in the drug development process in academic laboratories, with the potential that novel targeted therapies may eventually be evaluated and benefit patients.
"LLS funds research to advance more breakthrough therapies for cancer patients. This funding support is specifically designed to advance promising compounds in the earliest stages of development," said Lee Greenberger, Ph.D., LLS chief scientific officer. "It is critically important that leading scientists and researchers get financial resources to pursue innovative, novel approaches that can change the standard of care for patients with blood cancers."
The amounts of the grants awarded to these innovative researchers will vary and be determined on a case by case basis. The awardees are:
Li Chai, M.D. – Brigham and Women's, Boston
Chai will target SALL4 in the treatment of acute myeloid leukemia (AML). SALL4 is a transcription factor – a protein that regulates genetic activity, and is abnormally expressed in most AML patient samples. Chai's team has been testing a peptide that can block SALL4. While peptides can be useful as tools, they have low stability in the body so the team is performing high throughput tests to identify other compounds with drug-like characteristics that might also be effective in blocking SALL4. The team has produced an assay, a laboratory test that enables researchers to examine thousands of compounds, that will be used by a contract research organization (CRO) to identify those that are effective against SALL4.
Michael Deininger, M.D., Ph.D. – Huntsman Cancer Institute, Salt Lake City
Signal Transducer and Activator of Transcription 3 (STAT3) is a protein involved in the regulation of cell growth and survival. It is frequently super-activated in patients with certain cancers. Deininger has developed assays to identify STAT3 inhibitors and through medicinal chemistry approaches, has generated more potent inhibitors. The grant will assist him in his goal of making compounds more effective at inhibiting STAT3 at lower doses. Promising compounds will be synthesized on a larger scale and will be tested in animal models of therapy-resistant chronic myeloid leukemia (CML) as well as in myelofibrosis (MF). Since STAT3 is activated in a number of cancers, compounds developed may be useful beyond CML and MF.
Yali Dou, Ph.D. – University of Michigan
Epigenetics are small chemical modifications that alter gene activity without changing the DNA code of those genes. Abnormal epigenetic changes are often associated with the growth of cancer cells. A protein known as mixed-lineage leukemia protein (MLL) works with a host of other proteins to mediate such epigenetic alterations and is genetically altered in certain patients with AML resulting in a particularly poor prognosis for these patients. Dou's team has developed an assay whereby purified MLL and its associated co-regulator proteins are mixed, and their epigenetic modifying activity can be quantitatively measured. They will screen large libraries of compounds with drug-like characteristics in this assay, and determine which ones can inhibit the epigenetic modifying activity. Positive hits in the screen will be used as lead compounds for improvement, which can then be tested in cancer models as antitumor agents.
Aaron Schimmer, M.D., Ph.D. – Princess Margaret Cancer Center/Ontario Cancer Institute
The proteasome is a machine in the cell that regulates the degradation of proteins in the cells, and is essential to getting rid of proteins no longer needed. In addition, the proteasome is crucial to the normal cell signaling process required for growth and survival of the cell. Certain cancer cells, such as those found in patients with multiple myeloma, have high levels of proteasome activity. Thus, inhibiting the proteasome has been an effective anti-cancer therapy, as is the case of Velcade® in patients with multiple myeloma. Velcade targets the proteasome in the cytoplasm. Schimmer has recently shown that inhibiting the proteasome in the mitochondria (energy factory) has anti-tumor activity. This is a novel approach to cancer therapy, and the identification of a drug specifically targeting the mitochondrial proteasome may lead to a first-in-class drug for treatment of patients with AML and potentially other cancers.
David Williams, M.D. – Children's Hospital Boston
The Rac proteins are required for cancer development in a number of systems. Williams has explored the role of these proteins in CML, AML, and more recently, acute lymphocytic leukemia (ALL). His team has shown that inhibition of Rac can lead to cancer cell death. From previously LLS-funded research, compounds were identified that inhibit Rac and were tested as anti-cancer agents. They successfully identified a number of lead compounds worthy of further refinement. The purpose of this grant is to continue the project to use a medicinal chemistry approach to improve these compounds, potentially identifying lead compounds that may be candidates for clinical evaluation.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Contact: Andrea Greif
SOURCE The Leukemia & Lymphoma Society
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Aug. 3, 2015 11:30 PM EDT Reads: 237
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Aug. 3, 2015 11:00 PM EDT Reads: 692
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Aug. 3, 2015 10:45 PM EDT Reads: 218
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Aug. 3, 2015 06:45 PM EDT Reads: 533
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Aug. 3, 2015 05:45 PM EDT
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Aug. 3, 2015 04:00 PM EDT Reads: 276
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Aug. 3, 2015 03:45 PM EDT
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
Aug. 3, 2015 03:30 PM EDT
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Aug. 3, 2015 03:15 PM EDT
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Aug. 3, 2015 03:00 PM EDT Reads: 560
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Aug. 3, 2015 12:30 PM EDT Reads: 208
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Aug. 3, 2015 09:45 AM EDT Reads: 367
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Aug. 3, 2015 07:30 AM EDT Reads: 193
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Aug. 2, 2015 06:00 PM EDT Reads: 1,138
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
Aug. 2, 2015 04:00 PM EDT Reads: 435